TXMD vs. OSMT, CUE, PRPH, LFVN, TLSA, ETON, PMVP, ASRT, ORMP, and RLMD
Should you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Osmotica Pharmaceuticals (OSMT), Cue Biopharma (CUE), ProPhase Labs (PRPH), LifeVantage (LFVN), Tiziana Life Sciences (TLSA), Eton Pharmaceuticals (ETON), PMV Pharmaceuticals (PMVP), Assertio (ASRT), Oramed Pharmaceuticals (ORMP), and Relmada Therapeutics (RLMD). These companies are all part of the "medical" sector.
TherapeuticsMD (NASDAQ:TXMD) and Osmotica Pharmaceuticals (NASDAQ:OSMT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking.
TherapeuticsMD has higher earnings, but lower revenue than Osmotica Pharmaceuticals.
TherapeuticsMD received 309 more outperform votes than Osmotica Pharmaceuticals when rated by MarketBeat users. Likewise, 62.16% of users gave TherapeuticsMD an outperform vote while only 57.89% of users gave Osmotica Pharmaceuticals an outperform vote.
TherapeuticsMD has a net margin of 0.00% compared to Osmotica Pharmaceuticals' net margin of -138.76%. TherapeuticsMD's return on equity of -21.15% beat Osmotica Pharmaceuticals' return on equity.
30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 46.2% of Osmotica Pharmaceuticals shares are held by institutional investors. 1.2% of TherapeuticsMD shares are held by insiders. Comparatively, 5.2% of Osmotica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, TherapeuticsMD had 4 more articles in the media than Osmotica Pharmaceuticals. MarketBeat recorded 4 mentions for TherapeuticsMD and 0 mentions for Osmotica Pharmaceuticals. TherapeuticsMD's average media sentiment score of 1.19 beat Osmotica Pharmaceuticals' score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the media.
TherapeuticsMD has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Osmotica Pharmaceuticals has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.
Summary
TherapeuticsMD beats Osmotica Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
Get TherapeuticsMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TherapeuticsMD Competitors List
Related Companies and Tools
